Dr. Samuel S Newman, M.D. Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Medical Village Dr, Edgewood, KY 41017 Phone: 859-344-1600 Fax: 859-344-0091 |
Dr. James F Bardgett Jr., M.D. Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Medical Village Dr, Edgewood, KY 41017 Phone: 859-344-1600 Fax: 859-344-0091 |
Alhasan Sedeeq, M.D. Surgery - Vascular Surgery Medicare: Accepting Medicare Assignments Practice Location: 20 Medical Village Dr, Edgewood, KY 41017 Phone: 859-344-1600 Fax: 859-344-0091 |
News Archive
Oncolytics Biotech Inc. announced today that following submission to the U.S. Food and Drug Administration for review, the Company is initiating a U.S. Phase I study of REOLYSIN(R) in combination with FOLFIRI (Folinic Acid (leucovorin) + Fluorouracil (5-FU) + Irinotecan) in patients with oxaliplatin refractory/intolerant Kras mutant colorectal cancer.
Fortification of corn masa flour products could increase folic acid intake by nearly 20 percent for Mexican-Americans, who are at a 30-40 percent higher risk for a number of severe brain and spinal birth defects, according to a study by the Centers for Disease Control and Prevention (CDC).
Many plans sold through the health law's marketplaces don't cover weight loss surgery, and none in Louisiana are accepting payments from a federal program intended to help people with HIV/AIDS. The New York Times explores who benefits from the latest employer mandate extension, and Kaiser Health News answers a question about the health law's impact on a person covered by COBRA.
"Anti-poverty advocates are urging President Obama to 'find political will to end global hunger' during the upcoming G8 Summit at Camp David," Inter Press Service reports. Members of ActionAid last week held signs in front of the White House "that read 'Obama: Find the Will to be a Hunger Hero at the G8,' next to a cutout of the president in a superhero suit," the news service writes.
Promosome LLC, a biotechnology company uniquely dedicated to the development of technologies related to the regulation of protein synthesis through translation initiation, today announced the signing of a technology license and partnership agreement with Recopharma AB of Stockholm, Sweden. Recopharma is a recognized leader in the research and development of therapeutic recombinant mucin-type fusion proteins.
› Verified 1 days ago